Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company in Boston, is developing Anticalin-based drugs for the treatment of cancer, asthma, anemia and other conditions that show a high unmet medical need. Pieris’ drugs are created in a unique and transformative way, using immuno-oncology multi-specifics tailored for the tumor microenvironment, in addition to an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Through the development of Anticalin proteins, the company produces low-molecular-weight therapeutic proteins derived from lipocalins. These proteins are naturally occurring, low-molecular-weight human proteins found in blood plasma and other bodily fluids. The company’s pipeline currently has three drug candidates in development, one of which is PRS-080, designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis. The company is also developing PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. Lastly, Pieris is also developing PRS-343, a bispecific protein for oncology diseases. The company collaborates with a wide range of larger companies to aid in the development of their product candidates, including Allergan, Inc, Sanofi Group and La Roche. For more on Pieris, visit the company’s website.